title: Tumour necrosis factor blockade mediates altered serotonin transporter availability in rheumatoid arthritis: a clinical, proof-of-concept study.
authors.forename: Jonathan
authors.initials: J
authors.lastname: Cavanagh
authors.forename: Carolyn
authors.initials: C
authors.lastname: Paterson
authors.forename: John
authors.initials: J
authors.lastname: McLean
authors.forename: Sally
authors.initials: S
authors.lastname: Pimlott
authors.forename: Moira
authors.initials: M
authors.lastname: McDonald
authors.forename: James
authors.initials: J
authors.lastname: Patterson
authors.forename: David
authors.initials: D
authors.lastname: Wyper
authors.forename: Iain
authors.initials: I
authors.lastname: McInnes
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000378:metabolism; D001921:Brain / Q000378:metabolism; D006801:Humans; D050486:Serotonin Plasma Membrane Transport Proteins / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D050486:Serotonin Plasma Membrane Transport Proteins; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab